statistiche ricercatore

Continente	#
NA - Nord America	884
AS - Asia	353
EU - Europa	340
SA - Sud America	74
Continente sconosciuto - Info sul continente non disponibili	24
AF - Africa	16
OC - Oceania	1
Totale	1.692

Nazione	#
US - Stati Uniti d'America	862
SG - Singapore	173
IT - Italia	79
CN - Cina	70
SE - Svezia	64
BR - Brasile	60
FR - Francia	48
DE - Germania	35
VN - Vietnam	30
IE - Irlanda	24
FI - Finlandia	23
GB - Regno Unito	16
CA - Canada	15
IN - India	15
ID - Indonesia	13
PL - Polonia	10
AT - Austria	8
ES - Italia	8
HK - Hong Kong	8
JP - Giappone	8
RU - Federazione Russa	8
AR - Argentina	7
BD - Bangladesh	7
ZA - Sudafrica	7
PK - Pakistan	6
TR - Turchia	6
CI - Costa d'Avorio	4
MA - Marocco	4
UZ - Uzbekistan	4
CO - Colombia	3
IR - Iran	3
NL - Olanda	3
VE - Venezuela	3
BE - Belgio	2
GT - Guatemala	2
IQ - Iraq	2
KZ - Kazakistan	2
MX - Messico	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AU - Australia	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CH - Svizzera	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
GL - Groenlandia	1
GR - Grecia	1
IL - Israele	1
IM - Isola di Man	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
LT - Lituania	1
MD - Moldavia	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TW - Taiwan	1
UA - Ucraina	1
Totale	1.669

Nome	#
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV	319
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study	284
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	161
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice	153
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	137
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice	125
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice	120
Evaluation of doravirine-based regimen population target in a large Italian clinical center	104
People Living with HIV in the COVID-19 Era: A Case Report	102
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV	97
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al	90
Totale	1.692

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	73	0	1	0	5	0	1	5	9	2	2	7	41
2022/2023	297	33	41	14	48	10	34	12	40	38	2	21	4
2023/2024	143	4	27	1	10	4	21	15	4	10	12	18	17
2024/2025	254	3	3	51	11	14	15	15	7	35	23	36	41
2025/2026	535	88	9	28	58	109	25	75	27	57	36	18	5
2026/2027	349	20	329	0	0	0	0	0	0	0	0	0	0
Totale													1.692

IRIS UniCatt